Phase II data deliver conditional EU approval for Roche cancer drug

21 February 2017

Swiss pharmaceutical giant Roche (ROG: SIX) has been granted conditional approval from the European Medicines Agency (EMA) for its lung cancer therapy Alecensa (alectinib).

Under the provisions of the conditional approval, Roche will provide additional data on first-line Alecensa from an ongoing Phase III study. These results are expected within months.

The drug has been granted marketing authorization as a monotherapy for the treatment of certain adult patients with non-small cell lung cancer (NSCLC). This very serious condition is the leading cause of cancer-related deaths in Europe and across the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK